✦ LIBER ✦

BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

✍ Scribed by A. G. G. TURPIE; W. D. FISHER; K. A. BAUER; L. M. KWONG; M. W. IRWIN; P. KÄLEBO; F. MISSELWITZ; M. GENT; FOR THE ODIXa-KNEE STUDY GROUP

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral, direct Factor Xa inhibition with B

✍ B. I. ERIKSSON; L. BORRIS; O. E. DAHL; S. HAAS; M. V. HUISMAN; A. K. KAKKAR; F. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

A dose-ranging study evaluating the oral

✍ T. FUJI; S. FUJITA; S. TACHIBANA; Y. KAWAI 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB

A phase II study of the oral factor Xa i

✍ G. AGNELLI; S. HAAS; J. S. GINSBERG; K. A. KRUEGER; A. DMITRIENKO; J. T. BRANDT 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 533 KB

Prevention of venous thromboembolism wit

✍ B. I. ERIKSSON; A. G. G. TURPIE; M. R. LASSEN; M. H. PRINS; G. AGNELLI; P. KÄLEB 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

A dose escalation study of YM150, an ora

✍ B. I. ERIKSSON; A. G. G. TURPIE; M. R. LASSEN; M. H. PRINS; G. AGNELLI; P. KÄLEB 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 569 KB

AVE5026, a new hemisynthetic ultra-low-m

✍ M. R. LASSEN; O. E. DAHL; P. MISMETTI; D. DESTRÉE; A. G. G. TURPIE 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB